This seminar series will be discussing issues of generalizability, transportability, and representation in Alzheimer’s disease (AD) diagnosis and clinical trials. We will be considering the role of AD biomarkers and other eligibility criteria in determining who enters the clinical trials and cohort studies on which we base our conclusions and clinical recommendations.
When Research Funding Disappears, So Does the Promise Made to Participants
A recent investigation from The Guardian (Sept. 17, 2026) is a sobering reminder of how research funding decisions ripple far beyond a grant number on a spreadsheet. What happened: A federally funded study examining Alzheimer's disease risk among roughly 600 older...








